Oculis Holding AG (OCS) Interest Expenses (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Interest Expenses of -$220921.8 in Q1 2026, up 26.73% quarter-over-quarter from -$301531.9 in Q4 2025, and up 19.58% on a YoY basis from -$184741.0 in Q1 2025.
Oculis Holding AG (OCS) Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Interest Expenses history runs 5 years deep, the most recent figure standing at -$220921.8 for Q1 2026.
- In Q1 2026, Interest Expenses rose 19.58% year-over-year to -$220921.8; the TTM figure through Mar 2026 stood at -$203.3 million (up 33.44% YoY), while the FY2025 annual figure was -$1.0 million, down 42.88% from the prior year.
- Interest Expenses was -$220921.8 for Q1 2026 at Oculis Holding AG, up from -$301531.9 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of -$12453.7 in Q3 2023 to a low of -$304.7 million in Q3 2024.
- Historically, Interest Expenses has averaged -$32.2 million across 5 years, with a median of -$278340.9 in 2025.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses surged 99.34% in 2023, then plunged 2446652.74% in 2024.
- A 5-year view of Interest Expenses shows it stood at -$1.4 million in 2022, then surged by 99.01% to -$13528.3 in 2023, then plunged by 1984.2% to -$281955.9 in 2024, then declined by 6.94% to -$301531.9 in 2025, then increased by 26.73% to -$220921.8 in 2026.
- The last three Interest Expenses figures came in at -$220921.8 (Q1 2026), -$301531.9 (Q4 2025), and -$202.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -5.58 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -220,921.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -220,921.81 |
| Mar 31, 2026 | -220,921.81 |
| Dec 31, 2025 | -301,531.92 |
| Dec 31, 2025 | -301,531.92 |
| Sep 30, 2025 | -202.52 Mn |
| Sep 30, 2025 | -202.52 Mn |
| Jun 30, 2025 | -221,043.91 |
| Jun 30, 2025 | -221,043.91 |
| Mar 31, 2025 | -274,725.88 |
| Mar 31, 2025 | -274,725.88 |
| Dec 31, 2024 | -281,955.90 |
| Dec 31, 2024 | -281,955.90 |
| Sep 30, 2024 | -304.71 Mn |
| Sep 30, 2024 | -304.71 Mn |
| Jun 30, 2024 | -96,204.03 |
| Jun 30, 2024 | -96,204.03 |
| Mar 31, 2024 | -46,972.97 |
| Mar 31, 2024 | -46,972.97 |
| Dec 31, 2023 | -13,528.25 |
| Dec 31, 2023 | -13,528.25 |